BCL2L1 and cancer: For example, volasertib can cause downregulated BCL2L1 expression, disrupt the interaction between PLK1 and NEK7, or displacement of HMGB2 from mitotic chromosomes, thereby affecting mitotic arrest and apoptosis in cancer cells.